: Through this application Emory University, Duke University, the Orlando Immunology Center, and the Centers for Disease Control and Prevention (CDC) are proposing an integration of eight existing, highly productive HIV research sites. The administrative core of the Emory, Duke, Orlando, CDC Clinical Trials Unit (EmDOC CTU) will be located at Emory University. The CTU will be led by three Principal Investigators: Carlos del Rio, Jeffrey Lennox, and Mark J. Mulligan. The CTU will include four Southeastern US research sites (2 located in Atlanta, one in Durham, and one in Orlando) and four international research sites (Botswana, Kenya, Tanzania, and Thailand). All of these sites are currently performing complex clinical trials in areas of the United States and internationally that are hard hit by the HIV epidemic, as well as by the concomitant epidemics of TB and viral hepatitis, and have access to diverse heavily affected populations.
The Specific Aims of the Project are: 1. To contribute scientific expertise and human subject enrollment into studies that address these six key research areas-Adult HIV therapeutic strategies, including HIV cure, noninfectious comorbidities, and the infectious comorbidities of hepatitis and tuberculosis; Strategies to address HIV and HIV-associated infections in pediatric and maternal populations; Integrated HIV prevention strategies; Microbicide strategies to prevent HIV infection; Vaccines to prevent HIV infection; and Strategies to address antibacterial resistance. 2. To be a leading CTU for contributions of women, minorities and adolescents to support Network clinical trials, both domestically and in low and middle income countries. 3. To operate an efficient and flexible CTU that can respond rapidly to evolving research opportunities. 4. To participate in the development and implementation of the clinical research plans of all of the NIAID clinical research networks that are addressing the six priority research areas.
The CTU, working with the clinical research networks, will contribute to the development of improved strategies for the treatment and potential cure of HIV infection, to the treatment of TB and viral hepatitis, to improved methods for the prevention of HIV, and to improved treatments for antibiotic resistant infections. This CTU will contribute to improving the health of both the American public and the international public.
|Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912|
|Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187|
|Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459|
|Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524|
|Latkin, Carl A; Van Tieu, Hong; Fields, Sheldon et al. (2017) Social Network Factors as Correlates and Predictors of High Depressive Symptoms Among Black Men Who Have Sex with Men in HPTN 061. AIDS Behav 21:1163-1170|
|Anderson, Albert M; Lennox, Jeffrey L; Mulligan, Mark M et al. (2017) Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. J Neurovirol 23:106-112|
|Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111|
|Rolle, Charlotte-Paige; Rosenberg, Eli S; Siegler, Aaron J et al. (2017) Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM. J Acquir Immune Defic Syndr 76:250-258|
|Ofotokun, Ighovwerha; Titanji, Kehmia; Vunnava, Aswani et al. (2016) Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. AIDS 30:405-14|
|Ofotokun, Ighovwerha; Titanji, Kehmia; Lahiri, Cecile D et al. (2016) A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial. Clin Infect Dis 63:663-671|
Showing the most recent 10 out of 81 publications